SPOTLIGHT: Chantix scrips drop 5% on FDA alert

Prescriptions for Pfizer's stop-smoking drug Chantix dropped 5 percent last week after the FDA called it "increasingly likely" that there is a link between use of the drug and various neuro-psychiatric symptoms, including suicidal behavior. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.